A study led by PATH has estimated a financial cost of $0.27 and economic cost of $3.88 per dose of human papillomavirus (HPV) vaccine delivered as part of a routinized program in Sri Lanka. Researchers conducted a retrospective operational research and microcosting study focusing on 2019, and collected data from 30 divisional health units, 10 districts, and the central level. Cost drivers identified included the opportunity cost of health worker and non-health worker time at the divisional health unit level and capital costs for vehicles and equipment, along with fuel, maintenance, and energy, at the district and central levels. This study provides new evidence on the cost and cost drivers of a routinized HPV vaccination program. Results can be used for financial planning purposes in Sri Lanka and may inform other countries as they consider use of HPV vaccines.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.